

**Chandler Regional Medical Center and Mercy Gilbert Medical Center  
Policy and Procedure**

**SUBJECT**        Nephrogenic Systemic Fibrosis **(RAD.030)**

<b>APPLIES TO</b>	<input checked="" type="checkbox"/> Chandler Regional Medical Center
	<input checked="" type="checkbox"/> Mercy Gilbert Medical Center

*Printed copies are for reference only. Please refer to electronic copy for the latest version.*

**PURPOSE**

To minimize the risk of Nephrogenic Systemic Fibrosis (NSF), a disease associated with the administration of Gadolinium-Based Contrast Agents (GBCA) in patients with impaired renal function.

**PROCEDURE**

1. Only ACR Group II agents such as gadoteridol (ProHance), gadoxetate disodium (Eovist), and gadopichlenol (Vueway) are to be used under this policy.
2. All patients with orders for contrast-enhanced MRI must be screened for a history of dialysis.
3. If the patient is on dialysis, the MRI technologist will notify a radiologist to review the case.
4. The radiologist will review the case and the indication for the use of a gadolinium-based contrast agent, discussing with the ordering provider if deemed necessary.
5. The MRI technologist will then proceed as instructed by the radiologist.
6. If utilizing a GBCA, the scan will be timed as close to regularly scheduled dialysis as possible.

**APPROVALS**

Radiology Department, June 12, 2025

Ed Jones, Director, Imaging Services

Dr. Yagnesh Patel, Chief Medical Officer, Arizona Market

**ORIGINATION DATE**

October 10, 2024

**REVIEW/REVISION DATE**

7/25